Chemotherapy Chosen By More Older Women With Early Stage Breast Cancer

May 16, 2009

A new study examining treatment decision-making by older women with early stage breast cancer shows that 45 percent of women would choose to get chemotherapy after surgery — a figure higher than the national average of women getting the additional treatment.

“This was an unexpected finding,” says the study’s lead investigator, Jeanne Mandelblatt, MD, MPH, associate director for population sciences at GUMC’s Lombardi Comprehensive Cancer Center and professor of oncology and medicine at GUMC. “While these numbers are in contrast with the uniformly high use of chemotherapy in younger early-stage breast cancer patients, they suggest that older women are learning more about their disease and may be weighing the risks and benefits more thoroughly.”
Read the rest of this entry »

Advertisements

Palonosetron Warrants Adequate Caloric Intake In Oncology Patients Receiving High Emetogenic Chemotherapy

March 23, 2009

A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland

New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer and Nutrition in Zurich shows that palonosetron, a second generation 5-HT3 receptor antagonist, warrants adequate caloric intake in oncology patients receiving high emetogenic chemotherapy (HEC). The result comes from an innovative study conducted in the Oncology Institute of Ospedale V. Fazzi of Lecce, Italy, by the research team of Dr. Vito Lorusso. The findings confirmed the efficacy of a single dose of palonosetron and dexamethasone to control chemotherapy-induced nausea and vomiting (CINV) episodes in patients treated with HEC (cisplatin and/or epirubicin and/or iphosphamide) for soft tissue sarcoma: 76% of the patients achieved complete response (no vomiting, no use of rescue medication), 74% complete control (complete response and no more than mild nausea), in the 7-day period following chemotherapy, after palonosetron treatment.
Read the rest of this entry »


Scientists Trial Device To Treat Chemotherapy Related Nausea

March 21, 2009

Trials to test acupressure wrist bands as a drug-free alternative for chemotherapy-related nausea are to take place at the University of Liverpool.

More than 75% of patients undergoing chemotherapy experience nausea, which can impact negatively on their quality of life. Acupressure wrist bands can reduce the symptoms of travel sickness by applying force to the Nei Kuan pressure point on each wrist.

The national study of more than 700 patients, at nine NHS cancer centres, will now measure the cost and clinical effectiveness of acupressure wrist bands in reducing and controlling chemotherapy-related nausea. Led by Professor Mari Lloyd-Williams, from the University’s Academic Palliative and Supportive Care Studies Group, the team will analyse a wide range of patients, diagnosed with different types of cancer and undergoing chemotherapy, in order to discover which patient groups would most benefit from the intervention.
Read the rest of this entry »


Phase III Study Showed Rituxan In Combination With Chemotherapy Improved Progression-Free Survival In Patients With Relapsed Chronic Leukemia

January 7, 2009

Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for U.S. regulatory purposes.
Read the rest of this entry »


Patients With Stomach Cancer May Not Be Benefiting From A Major Study Showing Chemotherapy And Radiation Prolong Life After Surgery

December 25, 2008

New findings from Oregon Health & Science University Cancer Institute show significant numbers of patients nationwide who are not getting the recommended therapy after surgery to remove stomach cancer.

“We were surprised to learn that there are still many patients who are not receiving the gold standard of chemotherapy and radiation after surgery – despite compelling clinical data available since 2001. However, it is encouraging to see there has been a significant increase in the use of chemo-radiotherapy since it became the standard of care,” said Kristian Enestvedt, M.D., principal investigator, Department of Surgery, OHSU School of Medicine, OHSU Cancer Institute.
Read the rest of this entry »


Patients With Stomach Cancer May Not Be Benefiting From A Major Study Showing Chemotherapy And Radiation Prolong Life After Surgery

May 30, 2008

New findings from Oregon Health & Science University Cancer Institute show significant numbers of patients nationwide who are not getting the recommended therapy after surgery to remove stomach cancer.

“We were surprised to learn that there are still many patients who are not receiving the gold standard of chemotherapy and radiation after surgery – despite compelling clinical data available since 2001. However, it is encouraging to see there has been a significant increase in the use of chemo-radiotherapy since it became the standard of care,” said Kristian Enestvedt, M.D., principal investigator, Department of Surgery, OHSU School of Medicine, OHSU Cancer Institute.
Read the rest of this entry »